## Massimo Negrini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2397821/publications.pdf

Version: 2024-02-01

246 papers 48,147 citations

78 h-index 216 g-index

251 all docs

251 docs citations

251 times ranked

44270 citing authors

#	Article	IF	CITATIONS
1	Targeting CD99 Compromises the Oncogenic Effects of the Chimera EWS–FLI1 by Inducing Reexpression of Zyxin and Inhibition of GLI1 Activity. Molecular Cancer Therapeutics, 2022, 21, 58-69.	1.9	4
2	microRNAs and metabolism. , 2022, , 63-76.		O
3	microRNAs and Inflammatory Immune Response in SARS-CoV-2 Infection: A Narrative Review. Life, 2022, 12, 288.	1.1	10
4	Detection of diseaseâ€causing mutations in prostate cancer by NGS sequencing. Cell Biology International, 2022, 46, 1047-1061.	1.4	10
5	In chronic lymphocytic leukaemia, SLAMF1 deregulation is associated with genomic complexity and independently predicts a worse outcome. British Journal of Haematology, 2021, 192, 1068-1072.	1.2	5
6	Preliminary results from whole-genome expression analysis in patients with secondary adrenal insufficiency treated with modified-release hydrocortisone. Endocrine, 2021, 73, 177-185.	1.1	1
7	Unraveling the role of microRNA/isomiR network in multiple primary melanoma pathogenesis. Cell Death and Disease, 2021, 12, 473.	2.7	13
8	Longitudinal Circulating Levels of miR-23b-3p, miR-126-3p and lncRNA GAS5 in HCC Patients Treated with Sorafenib. Biomedicines, 2021, 9, 813.	1.4	11
9	The Molecular Networks of microRNAs and Their Targets in the Drug Resistance of Colon Carcinoma. Cancers, 2021, 13, 4355.	1.7	5
10	P2X7 promotes metastatic spreading and triggers release of miRNA-containing exosomes and microvesicles from melanoma cells. Cell Death and Disease, 2021, 12, 1088.	2.7	31
11	MiR-30e-3p Influences Tumor Phenotype through <i>MDM2</i> / <i>/<i>TP53</i> Axis and Predicts Sorafenib Resistance in Hepatocellular Carcinoma. Cancer Research, 2020, 80, 1720-1734.</i>	0.4	47
12	Small extracellular vesicles deliver miRâ€21 and miRâ€217 as proâ€senescence effectors to endothelial cells. Journal of Extracellular Vesicles, 2020, 9, 1725285.	5.5	104
13	Molecular testing on bronchial washings for the diagnosis and predictive assessment of lung cancer. Molecular Oncology, 2020, 14, 2163-2175.	2.1	20
14	Change of Title: From High-Throughput to BioTech. BioTech, 2020, 9, 18.	1.3	1
15	Molecular biomarkers predicting early development of endometrial carcinoma: A pilot study. European Journal of Cancer Care, 2019, 28, e13137.	0.7	9
16	Metformin prevents liver tumourigenesis by attenuating fibrosis in a transgenic mouse model of hepatocellular carcinoma. Oncogene, 2019, 38, 7035-7045.	2.6	55
17	The Importance of microRNAs in RAS Oncogenic Activation in Human Cancer. Frontiers in Oncology, 2019, 9, 988.	1.3	18
18	DNA methylation of shelf, shore and open sea CpG positions distinguish high microsatellite instability from low or stable microsatellite status colon cancer stem cells. Epigenomics, 2019, 11, 587-604.	1.0	29

#	Article	IF	Citations
19	MicroRNA-Based Prophylaxis in a Mouse Model of Cirrhosis and Liver Cancer. Molecular Therapy - Nucleic Acids, 2019, 14, 239-250.	2.3	14
20	Genetic dynamics in untreated CLL patients with either stable or progressive disease: a longitudinal study. Journal of Hematology and Oncology, 2019, 12, 114.	6.9	5
21	Animal Models of Hepatocellular Carcinoma Prevention. Cancers, 2019, 11, 1792.	1.7	10
22	KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591988554.	1.4	25
23	MicroRNAs in Animal Models of HCC. Cancers, 2019, 11, 1906.	1.7	25
24	HER2-Positive Lobular Versus Ductal Carcinoma of the Breast: Pattern of First Recurrence and Molecular Insights. Clinical Breast Cancer, 2018, 18, e1133-e1139.	1.1	9
25	In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics. British Journal of Haematology, 2018, 181, 229-233.	1.2	34
26	Non-coding RNAs in the reprogramming of glucose metabolism in cancer. Cancer Letters, 2018, 419, 167-174.	3.2	60
27	The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma. Cell Death and Disease, 2018, 9, 4.	2.7	68
28	Quantification of Circulating MicroRNAs by Droplet Digital PCR. Methods in Molecular Biology, 2018, 1768, 445-457.	0.4	21
29	High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy. Scientific Reports, 2018, 8, 4371.	1.6	14
30	Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low- and very-low-risk genetic profile. Leukemia, 2018, 32, 543-546.	3.3	4
31	LncRNAs as novel players in hepatocellular carcinoma recurrence. Oncotarget, 2018, 9, 35085-35099.	0.8	46
32	Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma. Oncotarget, 2018, 9, 15350-15364.	0.8	79
33	Differential expression of hsa-miR-221, hsa-miR-21, hsa-miR-135b, and hsa-miR-29c suggests a field effect in oral cancer. BMC Cancer, 2018, 18, 721.	1.1	33
34	miR-199a-3p Modulates MTOR and PAK4 Pathways and Inhibits Tumor Growth in a Hepatocellular Carcinoma Transgenic Mouse Model. Molecular Therapy - Nucleic Acids, 2018, 11, 485-493.	2.3	81
35	Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemia. Oncotarget, 2018, 9, 34398-34412.	0.8	11
36	In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3–Mediated Apoptosis. Clinical Cancer Research, 2017, 23, 3953-3965.	3.2	137

#	Article	IF	CITATIONS
37	Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapy. Leukemia, 2017, 31, 1894-1904.	3.3	33
38	Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers. Gut, 2017, 66, 1268-1277.	6.1	75
39	Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. Clinical Cancer Research, 2017, 23, 2891-2904.	3.2	122
40	N-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migration. Genome Biology, 2017, 18, 98.	3.8	97
41	Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts. Cancer Letters, 2017, 388, 320-327.	3.2	73
42	Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs. Nature Communications, 2017, 8, 1801.	5.8	36
43	Change of Title: Microarrays Becomes High-Throughput. High-Throughput, 2017, 6, 10.	4.4	1
44	An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness. Oncotarget, 2017, 8, 28008-28020.	0.8	13
45	In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI. Blood, 2017, 129, 3495-3498.	0.6	74
46	Change of Title: Microarrays Becomes High-Throughput. High-Throughput, 2017, 6, 1.	4.4	0
47	Characterisation of peripheral blood mononuclear cell microRNA in early onset psoriatic arthritis. Clinical and Experimental Rheumatology, 2017, 35, 113-121.	0.4	24
48	"IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.― Mediterranean Journal of Hematology and Infectious Diseases, 2016, 8, 2016047.	0.5	6
49	Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations. Journal of Hematology and Oncology, 2016, 9, 88.	6.9	35
50	Dissecting chronic lymphocytic leukemia with 13q- using microRNA expression profile. Leukemia Research, 2016, 47, 114-115.	0.4	3
51	Circulating Non-coding RNA as Biomarkers in Colorectal Cancer. Advances in Experimental Medicine and Biology, 2016, 937, 171-181.	0.8	26
52	Integrating miRNA and gene expression profiling analysis revealed regulatory networks in gastrointestinal stromal tumors. Epigenomics, 2016, 8, 1347-1366.	1.0	23
53	Circulating MicroRNA Quantification Using DNA-binding Dye Chemistry and Droplet Digital PCR. Journal of Visualized Experiments, 2016, , .	0.2	9
54	Cerebrospinal fluid amounts of HLA-G in dimeric form are strongly associated to patients with MRI inactive multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 245-249.	1.4	11

#	Article	IF	CITATIONS
55	TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia. Cell Death and Disease, 2016, 7, e2071-e2071.	2.7	40
56	Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers. Oncotarget, 2016, 7, 82700-82711.	0.8	54
57	miRNA array screening reveals cooperative MGMT-regulation between miR-181d-5p and miR-409-3p in glioblastoma. Oncotarget, 2016, 7, 28195-28206.	0.8	34
58	Over-expression of the <i>miR-483-3p</i> overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma. Oncotarget, 2016, 7, 31361-31371.	0.8	45
59	Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients. BMC Cancer, 2015, 15, 808.	1.1	54
60	MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinomaâ€"a step towards personalized therapy. Clinical Epigenetics, 2015, 7, 129.	1.8	22
61	Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations. Genes Chromosomes and Cancer, 2015, 54, 818-826.	1.5	37
62	Absolute quantification of cell-free microRNAs in cancer patients. Oncotarget, 2015, 6, 14545-14555.	0.8	103
63	Increase of microRNA-210, Decrease of Raptor Gene Expression and Alteration of Mammalian Target of Rapamycin Regulated Proteins following Mithramycin Treatment of Human Erythroid Cells. PLoS ONE, 2015, 10, e0121567.	1.1	28
64	Circulating microRNAs, miR-939, miR-595, miR-519d and miR-494, Identify Cirrhotic Patients with HCC. PLoS ONE, 2015, 10, e0141448.	1.1	113
65	Emerging role of microRNAs in the treatment of hepatocellular carcinoma. Gastrointestinal Cancer: Targets and Therapy, 2015, , 89.	5 <b>.</b> 5	0
66	MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab. Oncotarget, 2015, 6, 38695-38704.	0.8	67
67	Gene Expression Changes in Progression of Cervical Neoplasia Revealed by Microarray Analysis of Cervical Neoplastic Keratinocytes. Journal of Cellular Physiology, 2015, 230, 806-812.	2.0	49
68	miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance. Cell Death and Disease, 2015, 6, e1823-e1823.	2.7	74
69	Age related miRNA signature in mesenchymal progenitors reveals key players in cellular performance and fate. Cytotherapy, 2015, 17, S7.	0.3	0
70	Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2015, 56, 3150-3158.	0.6	23
71	Diagnostic and prognostic microRNAs in the serum of breast cancer patients measured by droplet digital PCR. Biomarker Research, 2015, 3, 12.	2.8	80
72	Epstein–Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival. EBioMedicine, 2015, 2, 572-582.	2.7	43

#	Article	IF	Citations
73	Micromarkers 2.0: an update on the role of microRNAs in cancer diagnosis and prognosis. Expert Review of Molecular Diagnostics, 2015, 15, 1369-1381.	1.5	31
74	MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches. Cell Death and Differentiation, 2015, 22, 46-57.	5.0	140
75	Mesenchymal Progenitors Aging Highlights a miR-196 Switch Targeting HOXB7 as Master Regulator of Proliferation and Osteogenesis. Stem Cells, 2015, 33, 939-950.	1.4	56
76	Interspecies Gene Name Extrapolation—A New Approach. PLoS ONE, 2015, 10, e0138751.	1.1	5
77	miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eμ-TCL1 mouse model. Oncotarget, 2015, 6, 19807-19818.	0.8	29
78	Abstract 3974: A preclinical study for miR181b as the rapeutic in Eu-TCL1FL-tg mouse model for CLL. , 2015, , .		0
79	Abstract 3964: How to fish a good micro-marker out from a worthless lake: The case of cell-free miR-181a-5p and breast cancer. , 2015, , .		0
80	p53/mdm2 Feedback Loop Sustains miR-221 Expression and Dictates the Response to Anticancer Treatments in Hepatocellular Carcinoma. Molecular Cancer Research, 2014, 12, 203-216.	1.5	43
81	Cellular and Kaposi's sarcoma-associated herpes virus microRNAs in sepsis and surgical trauma. Cell Death and Disease, 2014, 5, e1559-e1559.	2.7	43
82	STAT3-mediated activation of microRNA cluster 17Â92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma. Haematologica, 2014, 99, 116-124.	1.7	50
83	Pluripotent Stem Cell miRNAs and Metastasis in Invasive Breast Cancer. Journal of the National Cancer Institute, 2014, 106, .	3.0	37
84	Quantification of Circulating miRNAs by Droplet Digital PCR: Comparison of EvaGreen- and TaqMan-Based Chemistries. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2638-2642.	1.1	78
85	Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in highâ€risk subgroups. Cancer Medicine, 2014, 3, 555-564.	1.3	21
86	OncomiR detection in circulating body fluids: a PDMS microdevice perspective. Lab on A Chip, 2014, 14, 4067-4075.	3.1	24
87	microRNAome Expression in Chronic Lymphocytic Leukemia: Comparison with Normal B-cell Subsets and Correlations with Prognostic and Clinical Parameters. Clinical Cancer Research, 2014, 20, 4141-4153.	3.2	52
88	Abstract 4785: miR-125b targets erythropoietin and its receptor and their expression correlates with metastatic potential and ERBB2/HER2 expression. , 2014, , .		2
89	Genetic subclonal complexity and miR125a-5p down-regulation identify a subset of patients with inferior outcome in low-risk CLL patients. Oncotarget, 2014, 5, 140-149.	0.8	10
90	Inhibiting the oncogenic mir-221 by microRNA sponge: toward microRNA-based therapeutics for hepatocellular carcinoma. Gastroenterology and Hepatology From Bed To Bench, 2014, 7, 43-54.	0.6	34

#	Article	IF	CITATIONS
91	HINCUTs in cancer: hypoxia-induced noncoding ultraconserved transcripts. Cell Death and Differentiation, 2013, 20, 1675-1687.	5.0	99
92	<i>CCAT2</i> , a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Research, 2013, 23, 1446-1461.	2.4	526
93	Small nucleolar RNAs as new biomarkers in chronic lymphocytic leukemia. BMC Medical Genomics, 2013, 6, 27.	0.7	73
94	Downregulation of the Mitochondrial Calcium Uniporter by Cancer-Related miR-25. Current Biology, 2013, 23, 58-63.	1.8	198
95	Clinical Monoclonal B Lymphocytosis versus Rai O Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features. Clinical Cancer Research, 2013, 19, 5890-5900.	3.2	60
96	<i>BCR/ABL1</i> -positive acute lymphoblastic leukemia relapsing as <i>BCR/ABL1</i> -negative acute lymphoblastic leukemia. Leukemia and Lymphoma, 2013, 54, 2065-2067.	0.6	1
97	miR-125b targets erythropoietin and its receptor and their expression correlates with metastatic potential and ERBB2/HER2 expression. Molecular Cancer, 2013, 12, 130.	7.9	73
98	miR-126&126* Restored Expressions Play a Tumor Suppressor Role by Directly Regulating ADAM9 and MMP7 in Melanoma. PLoS ONE, 2013, 8, e56824.	1.1	80
99	miR-221 affects multiple cancer pathways by modulating the level of hundreds messenger RNAs. Frontiers in Genetics, 2013, 4, 64.	1.1	42
100	Role of microRNAs in hepatocellular carcinoma: a clinical perspective. OncoTargets and Therapy, 2013, 6, 1167.	1.0	56
101	First Report of Circulating MicroRNAs in Tumour Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS). PLoS ONE, 2013, 8, e73443.	1.1	44
102	Anti-Tumor Activity of a miR-199-dependent Oncolytic Adenovirus. PLoS ONE, 2013, 8, e73964.	1.1	53
103	Stereotyped Subset #4 In Chronic Lymphocytic Leukemia Is Associated With Distinct Gene and Microrna Transcriptional Profile. Blood, 2013, 122, 1616-1616.	0.6	1
104	Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: <i>In Vitro</i> li> and <i>In Vivo</i> Evidence. Clinical Cancer Research, 2012, 18, 6260-6270.	3.2	213
105	MINT31 methylation in gastric noninvasive neoplasia. European Journal of Cancer Prevention, 2012, 21, 442-448.	0.6	3
106	Proliferation centers in chronic lymphocytic leukemia: correlation with cytogenetic and clinicobiological features in consecutive patients analyzed on tissue microarrays. Leukemia, 2012, 26, 499-508.	3.3	57
107	miRâ€34a predicts survival of Ewing's sarcoma patients and directly influences cell chemoâ€sensitivity and malignancy. Journal of Pathology, 2012, 226, 796-805.	2.1	128
108	In hepatocellular carcinoma <i>miRâ€519d</i> is upâ€regulated by p53 and DNA hypomethylation and targets <i>CDKN1A/p21, PTEN, AKT3</i> and <i>TIMP2</i> Journal of Pathology, 2012, 227, 275-285.	2.1	180

#	Article	IF	CITATIONS
109	Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. Hepatology, 2012, 56, 1025-1033.	3.6	150
110	Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with "normal―FISH: correlations with clinicobiologic parameters. Blood, 2012, 119, 2310-2313.	0.6	64
111	Diagnostic work-up for clinical and prognostic assessment of acute leukaemia. Rivista Italiana Della Medicina Di Laboratorio, 2012, 8, 26-35.	0.2	1
112	DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. Oncotarget, 2012, 3, 1246-1258.	0.8	138
113	MicroRNAs Dysregulation in Human Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2011, 6, 844-851.	0.5	77
114	microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. Oncogene, 2011, 30, 4750-4756.	2.6	600
115	MicroRNA response to environmental mutagens in liver. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2011, 717, 67-76.	0.4	24
116	MicroRNAs: Toward the Clinic for Breast Cancer Patients. Seminars in Oncology, 2011, 38, 764-775.	0.8	30
117	MicroRNA profiling for the identification of cancers with unknown primary tissueâ€ofâ€origin. Journal of Pathology, 2011, 225, 43-53.	2.1	117
118	microRNA Involvement in Hepatocellular Carcinoma. Anti-Cancer Agents in Medicinal Chemistry, 2011, 11, 500-521.	0.9	88
119	Mutated $\hat{l}^2$ -catenin evades a microRNA-dependent regulatory loop. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 4840-4845.	3.3	48
120	Association of a MicroRNA/TP53 Feedback Circuitry With Pathogenesis and Outcome of B-Cell Chronic Lymphocytic Leukemia. JAMA - Journal of the American Medical Association, 2011, 305, 59.	3.8	256
121	MicroRNA profiling reveals that miR-21, miR486 and miR-214 are upregulated and involved in cell survival in Sézary syndrome. Cell Death and Disease, 2011, 2, e151-e151.	2.7	119
122	MicroRNAs in Cancer (An Overview)., 2011,, 1-71.		0
123	MiR-34a Replacement As a Novel Therapeutic Approach for Multiple Myeloma: Preclinical In Vitro and In Vivo Evidence. Blood, 2011, 118, 2910-2910.	0.6	0
124	Chromosome Aberrations by Conventional Karyotyping in Chronic Lymphocytic Leukemia Carrying No Aberration by Fluorescence in Situ Hybridization: Correlation with Prognostic Parameters and Clinical Features. Blood, 2011, 118, 1459-1459.	0.6	0
125	MicroRNA-mediated regulation of pancreatic cancer cell proliferation. Oncology Letters, 2010, 1, 565-568.	0.8	10
126	microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood, 2010, 116, 945-952.	0.6	200

#	Article	IF	CITATIONS
127	Reprogramming of miRNA networks in cancer and leukemia. Genome Research, 2010, 20, 589-599.	2.4	331
128	Altered miRNA expression in T regulatory cells in course of multiple sclerosis. Journal of Neuroimmunology, 2010, 226, 165-171.	1.1	188
129	Non-coding RNAs change their expression profile after Retinoid induced differentiation of the promyelocytic cell line NB4. BMC Research Notes, 2010, 3, 24.	0.6	27
130	Differential cytogenomics and miRNA signature of the Acute Myeloid Leukaemia Kasumi-1 cell line CD34+38â^ compartment. Leukemia Research, 2010, 34, 1287-1295.	0.4	15
131	A transcriptome-wide approach reveals the key contribution of NFI-A in promoting erythroid differentiation of human CD34+ progenitors and CML cells. Leukemia, 2010, 24, 1220-1223.	3.3	17
132	miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor- $\hat{l}_{\pm}$ in human breast cancer cells. Cell Death and Differentiation, 2010, 17, 246-254.	5.0	231
133	Associations of risk factors obesity and occupational airborne exposures with CDKN2A/p16 aberrant DNA methylation in esophageal cancer patients. Ecological Management and Restoration, 2010, 23, 597-602.	0.2	13
134	MiR-199a-3p Regulates mTOR and c-Met to Influence the Doxorubicin Sensitivity of Human Hepatocarcinoma Cells. Cancer Research, 2010, 70, 5184-5193.	0.4	389
135	Modulation of mismatch repair and genomic stability by miR-155. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6982-6987.	3.3	306
136	Oncogenic Role of <i>miR-483-3p</i> at the <i>IGF2/483</i> Locus. Cancer Research, 2010, 70, 3140-3149.	0.4	272
137	MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia. Molecular Cancer, 2010, 9, 123.	7.9	107
138	Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Review of Molecular Diagnostics, 2010, 10, 297-308.	1.5	237
139	Involvement of MicroRNAs in Human Cancer: Discovery and Expression Profiling. , 2010, , 69-104.		0
140	MicroRNA Fingerprints Identify miR-150 as a Plasma Prognostic Marker in Patients with Sepsis. PLoS ONE, 2009, 4, e7405.	1.1	273
141	MicroRNA-221 Targets Bmf in Hepatocellular Carcinoma and Correlates with Tumor Multifocality. Clinical Cancer Research, 2009, 15, 5073-5081.	3.2	298
142	MicroRNA expression changes during human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal, a product of lipid peroxidation. Free Radical Biology and Medicine, 2009, 46, 282-288.	1.3	55
143	MicroRNAs and cancerâ€"new paradigms in molecular oncology. Current Opinion in Cell Biology, 2009, 21, 470-479.	2.6	219
144	MiR-122/Cyclin G1 Interaction Modulates p53 Activity and Affects Doxorubicin Sensitivity of Human Hepatocarcinoma Cells. Cancer Research, 2009, 69, 5761-5767.	0.4	380

#	Article	IF	Citations
145	MicroRNA-199a-3p targets mTOR in human hepatocellular carcinoma. Digestive and Liver Disease, 2009, 41, A10.	0.4	O
146	Clinicobiologic importance of cytogenetic lesions in chronic lymphocytic leukemia. Expert Review of Hematology, 2009, 2, 305-314.	1.0	7
147	Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood, 2009, 114, 3872-3879.	0.6	179
148	Significance of Aberrant Expression of MicroRNAs in Cancer Cells. , 2009, , 1-12.		0
149	The methylator phenotype in microsatellite stable colorectal cancers is characterized by a distinct gene expression profile. Journal of Pathology, 2008, 214, 594-602.	2.1	47
150	MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene, 2008, 27, 5651-5661.	2.6	619
151	Isolation and characterization of CD146+ multipotent mesenchymal stromal cells. Experimental Hematology, 2008, 36, 1035-1046.	0.2	240
152	E2F1-Regulated MicroRNAs Impair TGFÎ <sup>2</sup> -Dependent Cell-Cycle Arrest and Apoptosis in Gastric Cancer. Cancer Cell, 2008, 13, 272-286.	7.7	818
153	MicroRNA involvement in hepatocellular carcinoma. Journal of Cellular and Molecular Medicine, 2008, 12, 2189-2204.	1.6	248
154	Breast cancer metastasis: a microRNA story. Breast Cancer Research, 2008, 10, 203.	2.2	177
155	MiR-15a and miR-16-1 cluster functions in human leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 5166-5171.	3.3	741
156	Genome Wide Identification of Recessive Cancer Genes by Combinatorial Mutation Analysis. PLoS ONE, 2008, 3, e3380.	1.1	12
157	Regulation of microRNA Expression: the Hypoxic Component. Cell Cycle, 2007, 6, 1425-1430.	1.3	132
158	Regulatory mechanisms of microRNAs involvement in cancer. Expert Opinion on Biological Therapy, 2007, 7, 1009-1019.	1.4	150
159	MicroRNAs in human cancer: from research to therapy. Journal of Cell Science, 2007, 120, 1833-1840.	1.2	222
160	Mechanisms causing imprinting defects in familial Beckwith–Wiedemann syndrome with Wilms' tumour. Human Molecular Genetics, 2007, 16, 254-264.	1.4	100
161	Tumor Suppressor Functions of <i>ARLTS1</i> in Lung Cancers. Cancer Research, 2007, 67, 7738-7745.	0.4	15
162	Micro-RNA profiling in kidney and bladder cancers. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 387-392.	0.8	566

#	Article	IF	Citations
163	Cyclin G1 Is a Target of miR-122a, a MicroRNA Frequently Down-regulated in Human Hepatocellular Carcinoma. Cancer Research, 2007, 67, 6092-6099.	0.4	782
164	Nidogen 1 and 2 gene promoters are aberrantly methylated in human gastrointestinal cancer. Molecular Cancer, 2007, 6, 17.	7.9	64
165	mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer. Molecular Cancer, 2007, 6, 54.	7.9	240
166	A MicroRNA Signature of Hypoxia. Molecular and Cellular Biology, 2007, 27, 1859-1867.	1.1	990
167	Identification of differentially expressed microRNAs by microarray: A possible role for microRNA genes in pituitary adenomas. Journal of Cellular Physiology, 2007, 210, 370-377.	2.0	203
168	Anticancer activity of an adenoviral vector expressing short hairpin RNA against BK virus T-ag. Cancer Gene Therapy, 2007, 14, 297-305.	2.2	7
169	Use of herpes simplex virus type 1-based amplicon vector for delivery of small interfering RNA. Gene Therapy, 2007, 14, 459-464.	2.3	22
170	Ultraconserved Regions Encoding ncRNAs Are Altered in Human Leukemias and Carcinomas. Cancer Cell, 2007, 12, 215-229.	7.7	681
171	A microRNA expression signature of human solid tumors defines cancer gene targets. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 2257-2261.	3.3	5,220
172	MicroRNA deregulation in human thyroid papillary carcinomas. Endocrine-Related Cancer, 2006, 13, 497-508.	1.6	463
173	Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion. Blood, 2006, 107, 2531-2535.	0.6	109
174	Identification of NUP98 abnormalities in acute leukemia: JARID1A (12p13) as a new partner gene. Genes Chromosomes and Cancer, 2006, 45, 437-446.	1.5	123
175	Alterations of the Tumor Suppressor Gene ARLTS1 in Ovarian Cancer. Cancer Research, 2006, 66, 10287-10291.	0.4	47
176	BK Virus, JC Virus and Simian Virus 40 Infection in Humans, and Association with Human Tumors. Advances in Experimental Medicine and Biology, 2006, 577, 319-341.	0.8	61
177	MicroRNA Function in Human Hematopoiesis: Identification of Lineage- and Stage-Specific Expression Profiles, Pivotal Targets and Regulatory Circuitries Blood, 2006, 108, 1197-1197.	0.6	0
178	Familial Cancer Associated with a Polymorphism in ARLTS1. New England Journal of Medicine, 2005, 352, 1667-1676.	13.9	119
179	miR-15 and miR-16 induce apoptosis by targeting BCL2. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 13944-13949.	3.3	3,287
180	Extensive modulation of a set of microRNAs in primary glioblastoma. Biochemical and Biophysical Research Communications, 2005, 334, 1351-1358.	1.0	1,009

#	Article	IF	Citations
181	MicroRNA Gene Expression Deregulation in Human Breast Cancer. Cancer Research, 2005, 65, 7065-7070.	0.4	3,719
182	A MicroRNA Signature Associated with Prognosis and Progression in Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2005, 353, 1793-1801.	13.9	2,255
183	Adenoviral transduction of TESTIN gene into breast and uterine cancer cell lines promotes apoptosis and tumor reduction in vivo. Clinical Cancer Research, 2005, 11, 806-13.	3.2	36
184	Frequent Aberrant Methylation of the CDH4 Gene Promoter in Human Colorectal and Gastric Cancer. Cancer Research, 2004, 64, 8156-8159.	0.4	96
185	Chronic lymphocytic leukemia with 6qâ^' shows distinct hematological features and intermediate prognosis. Leukemia, 2004, 18, 476-483.	3.3	99
186	Simian virus 40 infection in humans and association with human diseases: results and hypotheses. Virology, 2004, 318, 1-9.	1.1	108
187	An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 9740-9744.	3.3	906
188	Cryptic insertion producing twoNUP98/NSD1 chimeric transcripts in adult refractory anemia with an excess of blasts. Genes Chromosomes and Cancer, 2004, 41, 395-399.	1.5	34
189	MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 11755-11760.	3.3	1,238
190	Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 2999-3004.	3.3	3,753
191	Human homeobox geneHOXC13 is the partner of NUP98 in adult acute myeloid leukemia with $t(11;12)(p15;q13)$ . Genes Chromosomes and Cancer, 2003, 36, 420-423.	1.5	35
192	Oncogenic transformation by BK virus and association with human tumors. Oncogene, 2003, 22, 5192-5200.	2.6	134
193	Genetic chaos and antichaos in human cancers. Medical Hypotheses, 2003, 60, 258-262.	0.8	29
194	Multigene Methylation Analysis of Gastrointestinal Tumors. Molecular Diagnosis and Therapy, 2003, 7, 201-207.	1.3	18
195	The BCSC-1 locus at chromosome 11q23-q24 is a candidate tumor suppressor gene. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 11517-11522.	3.3	47
196	Multigene Methylation Analysis of Gastrointestinal Tumors. Molecular Diagnosis and Therapy, 2003, 7, 201-207.	1.3	33
197	Nonlinear partial differential equations and applications: Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 15524-15529.	3.3	4,641
198	NUP98 is fused to the NSD3 gene in acute myeloid leukemia associated with t(8;11)(p11.2;p15). Blood, 2002, 99, 3857-3860.	0.6	176

#	Article	IF	CITATIONS
199	Loss of methylation at chromosome 11p15.5 is common in human adult tumors. Oncogene, 2002, 21, 2564-2572.	2.6	52
200	Cloning and characterization of the common fragile site FRA6F harboring a replicative senescence gene and frequently deleted in human tumors. Oncogene, 2002, 21, 7266-7276.	2.6	79
201	Late appearance of the 11q22.3-23.1 deletion involving the ATM locus in B-cell chronic lymphocytic leukemia and related disorders. Clinico-biological significance. Haematologica, 2002, 87, 44-51.	1.7	39
202	Cloning and characterization of a senescence inducing and class II tumor suppressor gene in ovarian carcinoma at chromosome region 6q27. Oncogene, 2001, 20, 980-988.	2.6	73
203	Somatic frameshift mutations in the Bloom syndrome BLM gene are frequent in sporadic gastric carcinomas with microsatellite mutator phenotype. BMC Genetics, 2001, 2, 14.	2.7	19
204	Acquired Chromosome 11q Deletion Involving the Ataxia Teleangiectasia Locus in B-Cell Non-Hodgkin's Lymphoma: Correlation With Clinicobiologic Features. Journal of Clinical Oncology, 2000, 18, 2607-2614.	0.8	41
205	Genetic progression in microsatellite instability high (MSI-H) colon cancers correlates with clinico-pathological parameters: A study of the TGRβRII, BAX, hMSH3, hMSH6, IGFIIR and BLM genes. International Journal of Cancer, 2000, 89, 230-235.	2.3	101
206	Four novel non-random chromosome rearrangements in B-cell chronic lymphocytic leukaemia: 6p24-25 and 12p12-13 translocations, 4q21 anomalies and monosomy 21. British Journal of Haematology, 2000, 108, 559-564.	1.2	14
207	t(4;11)(q21;p15) translocation involving NUP98 and RAP1GDS1 genes: characterization of a new subset of T acute lymphoblastic leukaemia. British Journal of Haematology, 2000, 109, 788-793.	1.2	28
208	Low frequency of alterations of the $\hat{l}_{\pm}$ (PPP2R1A) and $\hat{l}_{2}$ (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms. Oncogene, 2000, 19, 1191-1195.	2.6	206
209	Gain of imprinting at chromosome 11p15: A pathogenetic mechanism identified in human hepatocarcinomas. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 5445-5449.	3.3	81
210	Cloning and characterization of two overlapping genes in a subregion at 6q21 involved in replicative senescence and schizophrenia. Gene, 2000, 252, 217-225.	1.0	24
211	Genetic progression in microsatellite instability high (MSIâ€H) colon cancers correlates with clinicoâ€pathological parameters: A study of the TGRRII, BAX, hMSH3, hMSH6, IGFIIR and BLM genes. International Journal of Cancer, 2000, 89, 230-235.	2.3	4
212	Transcriptional map of chromosome region 6q16â†'q21. Cytogenetic and Genome Research, 1999, 86, 263-266.	0.6	4
213	Refinement of the LOH region $1$ at $11q23.1$ deleted in human breast carcinomas and sublocalization of $11$ expressed sequence tags within the refined region. Oncogene, $1999$ , $18$ , $1635-1638$ .	2.6	25
214	Molecular prenatal diagnosis of ataxia telangiectasia heterozygosity by direct mutational assays. , 1999, 19, 542-545.		16
215	Exon structure and promoter identification of STIM1 (alias GOK), a human gene causing growth arrest of the human tumor cell lines G401 and RD. Cytogenetic and Genome Research, 1999, 86, 214-218.	0.6	50
216	Subchromosomal assignment <footref rid="foot01"><sup>1</sup></footref> of the TSSC1 gene to human chromosome band 11p15.5 near the HBB gene cluster. Cytogenetic and Genome Research, 1998, 83, 52-53.	0.6	4

#	Article	IF	CITATIONS
217	Molecular Cloning and Characterization of ZNF202: A New Gene at $11q23.3$ Encoding Testis-Specific Zinc Finger Proteins. Genomics, $1998$ , $52$ , $358-362$ .	1.3	34
218	Alternative splicing, genomic structure, and fine chromosome localization of REV3L. Cytogenetic and Genome Research, 1998, 83, 18-20.	0.6	32
219	Transcriptional map of 170-kb region at chromosome 11p15.5: Identification and mutational analysis of the BWR1A gene reveals the presence of mutations in tumor samples. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 3873-3878.	3.3	56
220	Molecular Cloning and Characterization of LOH11CR2A, a New Gene within a Refined Minimal Region of LOH at $11q23$ . Genomics, $1997$ , $46$ , $217-222$ .	1.3	34
221	Mapping of 22 new ESTs around a tumor suppressor gene and a senescence gene at 6q16â†'q21. Cytogenetic and Genome Research, 1997, 79, 97-100.	0.6	7
222	Chromosome aberrations in atypical chronic lymphocytic leukemia: a cytogenetic and interphase cytogenetic study. Leukemia, 1997, 11, 1933-1940.	3.3	37
223	Refined Subchromosomal Location of 21 Expressed Sequence Tags from Unknown Genes at Region 11p15. European Journal of Human Genetics, 1997, 5, 214-217.	1.4	0
224	The FHIT Gene at 3p14.2 Is Abnormal in Lung Cancer. Cell, 1996, 85, 17-26.	13.5	529
225	Physical Analysis of Part of Band 6q21 Harboring a Putative Tumor Suppressor Gene and a Putative Senescence Gene. DNA Sequence, 1996, 7, 43-45.	0.7	1
226	Exon-Scanning Mutation Analysis of the ATM Gene in Patients with Ataxia-T elangiectasia. European Journal of Human Genetics, 1996, 4, 352-355.	1.4	27
227	Involvement of the ALL-1 gene in a solid tumor Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 4922-4926.	3.3	34
228	A BK virus episomal vector for constitutive high expression of exogenous cDNAs in human cells. Archives of Virology, 1995, 140, 335-339.	0.9	10
229	A novel $t(9;11)(p22;q23)$ with ALL-1 gene rearrangement associated with progression of a myeloproliferative disorder to acute myeloid leukemia. Cancer Genetics and Cytogenetics, 1995, 83, 65-70.	1.0	2
230	The human immunodeficiency virus type-1 Tat protein upregulates Bcl-2 gene expression in Jurkat T-cell lines and primary peripheral blood mononuclear cells. Blood, 1995, 86, 3823-3834.	0.6	117
231	Characterization of the Mammalian YAP (Yes-associated Protein) Gene and Its Role in Defining a Novel Protein Module, the WW Domain. Journal of Biological Chemistry, 1995, 270, 14733-14741.	1.6	298
232	Multiple loci on human chromosome 11 control tumorigenicity of BK virus transformed cells. International Journal of Cancer, 1994, 57, 185-191.	2.3	13
233	Minor myeloid component in Ph chromosome-positive acute lymphoblastic leukaemia: correlation with cytogenetic pattern and implication for poor response to therapy. British Journal of Haematology, 1994, 87, 515-522.	1.2	15
234	A new chromosomal breakpoint in Ph positive, bcr negative chronic myelogenous leukemia. Cancer Genetics and Cytogenetics, 1992, 61, 11-13.	1.0	13

#	Article	IF	CITATIONS
235	Prevalence of the archetypal regulatory region and sequence polymorphisms in nonpassaged BK virus variants. Journal of Virology, 1991, 65, 5092-5095.	1.5	49
236	Characterization of BK virus variants rescued from human tumours and tumour cell lines. Journal of General Virology, 1990, 71, 2731-2736.	1.3	46
237	Expression of Herpes Simplex Virus 1 Glycoprotein B in Human Cells and Protection of Mice against Lethal Herpes Simplex Virus 1 Infection. Advances in Experimental Medicine and Biology, 1989, 257, 263-271.	0.8	0
238	Constitutive expression in human cells of herpes simplex virus type $1\mathrm{glycoprotein}$ B gene cloned in an episomal eukaryotic vector. Virology, $1988,167,284\text{-}288.$	1.1	20
239	Cooperation in Oncogenesis between BK Virus Early Region Gene and the Activated Human c-Harvey ras Oncogene. Journal of General Virology, 1988, 69, 2671-2679.	1.3	21
240	Molecular analysis of mbcl-2: Structure and expression of the murine gene homologous to the human gene involved in follicular lymphoma. Cell, 1987, 49, 455-463.	13.5	198
241	Molecular and biological properties of BK virus-IR, a BK virus variant isolated from a human tumor. Journal of Virology, 1986, 59, 500-505.	1.5	54
242	BK virus-plasmid expression vector that persists episomally in human cells and shuttles into Escherichia coli Molecular and Cellular Biology, 1984, 4, 1551-1560.	1.1	54
243	Episomal DNA of a BK virus variant in a human insulinoma. Journal of Medical Virology, 1983, 12, 37-49.	2.5	67
244	Oncogenity of BK virus for immunosuppressed hamsters. Archives of Virology, 1982, 73, 243-253.	0.9	29
245	Evidence for BK Virus as a Human Tumor Virus. , 0, , 431-460.		17
246	The Role of Micro-RNAs in Rheumatic Diseases: An Update. , 0, , .		1